Komori
Earnings7096StemCell InstituteInformation and Communications, Services and Others

First-Quarter Financial Results for the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

For the first quarter of the fiscal year ending March 2027, consolidated net sales were ¥722 million and operating income was ¥41 million. The full-year earnings forecasts and annual dividend forecast remain unchanged.

Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
40.962
million yen
Wording
Conditional
How definitive the wording is.

Results for this period

First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAP
Net Sales722million yenProgress 23.3%
Operating profit40million yenProgress 40.0%
Ordinary income43million yenProgress 43.0%
Net income attributable to owners of the parent35million yenProgress 33.3%

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.

Net income per share¥3.57
Financial position at period-end
Total assets8,515million yen
of which net assets 3,280 million yenEquity ratio 31.9%vs. prior year-end -1.1pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Full-year earnings forecast
Net Sales3,100 million yen (YoY +10.3%)
Operating profit100 million yen (YoY -50.7%)
Ordinary income100 million yen (YoY -54.0%)
Net income105 million yen (YoY -32.7%)
Annual Dividend Forecast0 yen → 0 yen(0.0%)
Factors Behind Changes in Business Performance

Although the cost of sales ratio increased due to higher personnel expenses and rising prices, the increase in selling, general and administrative expenses, particularly advertising expenses, was contained. The overseas business recorded an operating loss due to preparations for commencing operations.

Disclosure regarding the going concern assumption

No applicable matters

Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsAt a meeting of the Board of Directors held on 22 July 2026, the Company resolved to issue share acquisition rights as stock options for directors and employees of the Company and its subsidiaries, and made the allotments on the same date.
Depreciation and amortization44,447 thousand yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors
Issued Shares at Period-End10,246,600 shares
Treasury Shares at Period-End176,412 shares
Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedConsolidated
Period Covered1 April 2026 to 30 June 2026
Net Sales722 million yen
Operating profit40 million yen
Ordinary income43 million yen
Profit attributable to owners of the parent35 million yen
Net income per share¥3.57
Equity ratioEnd of the current fiscal period 31.9 / End of previous period 33
Total assets8,515 million yen
Net assets3,280 million yen
Full-year earnings forecastNet Sales 3,100 million yen (YoY +10.3%) / Operating profit 100 million yen (YoY -50.7%) / Ordinary income 100 million yen (YoY -54.0%) / Net income 105 million yen (YoY -32.7%)
Annual Dividend Forecast0 yen → 0 yen(0.0%)
Depreciation and amortization44,447 thousand yen
Disclosure regarding the going concern assumptionNo applicable matters
Change in accounting policyChanges due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsAt a meeting of the Board of Directors held on 22 July 2026, the Company resolved to issue share acquisition rights as stock options for directors and employees of the Company and its subsidiaries, and made the allotments on the same date.
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors
Issued Shares at Period-End10,246,600 shares
Treasury Shares at Period-End176,412 shares
Factors Behind Changes in Business PerformanceAlthough the cost of sales ratio increased due to higher personnel expenses and rising prices, the increase in selling, general and administrative expenses, particularly advertising expenses, was contained. The overseas business recorded an operating loss due to preparations for commencing operations.
Items this document does not state (14)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Although the cost of sales ratio increased due to higher personnel expenses and rising prices, the increase in selling, general and administrative expenses, including advertising expenses, was contained. The overseas business recorded an operating loss due to preparations for commencing operations.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
First-Quarter Financial Results for the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated) | StemCell Institute (7096) timely disclosure | Komori